TheEdgeResearch
Home / Stocks / BGM

BGM Group Ltd. (BGM)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$0.31 ▲ +5.33%
Market Cap
$116.7M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.81
52-Wk Range
0.25-11.8
CEO
Chen Xin
Country
CN
Currency
USD

BGM Group Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Chengdu, SIC, CN. The stock last traded at $0.31, up 5.33% on the session, giving a market capitalisation of $116.7M. On trailing twelve-month figures it carries a trailing P/E of -1.87, a net margin of -52.6%. Its beta of 1.81 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.87
Price / Sales
3.08
Price / Book
0.10
EV / EBITDA
-9.78
Gross margin
12.8%
Operating margin
-33.2%
Net margin
-52.6%
Return on equity
Debt / equity
0.00
Current ratio
1.24
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
298
IPO date
2021-01-12
Headquarters
Chengdu, SIC, CN
About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

Comparable companies

BGM Group Ltd. is most often compared with the following Healthcare names:

ANIPAVDLCLOVEWTXGPCRMESOPAHCPRCTQDELTWST
More research on BGM
BGM technical analysis BGM TheEdge Score Compare against peers
Open full interactive analysis & DCF →